TORONTO, Canada/MEDELLÍN, Colombia (February 1, 2017) — PharmaCielo Ltd. is pleased to congratulate board of directors member Carlos Manuel Uribe and PharmaCielo Colombia Holdings S.A.S. board member Luis Carlos Uribe for being recognized by the International Association of Horticultural Producers (AIPH) with the Grower of the Year award, in their leadership capacity with Flores El Capiro S.A.
Flores El Capiro S.A. is the world’s largest exporter of flowers by sea freight and one of the top three largest growers of chrysanthemums in the world. The award recognizes the company’s leadership in sea freight logistics, delivering cut flowers to its customers around the world through its innovative packaging. The company’s 1,800 employees produce 150 million top-quality chrysanthemum stems per year, grown in Rionegro, Antioquia, Colombia.
“PharmaCielo is honoured to have both Carlos Manuel and Luis Carlos associated with our boards of directors, and this prestigious recognition exemplifies the experience and talent of the Colombian flower industry with which we are partners,” said company president and CEO Patricio Stocker.
“The willingness of Colombia’s leading growers and exporters of cut flowers to apply their expertise, as demonstrated by Luis Carlos Uribe and Carlos Manuel Uribe, is a key element in PharmaCielo’s overall strategy of working with contract growers to develop rapidly scalable, large-volume cultivation of cannabis for oil extracts processing,” added Federico Cock-Correa, CEO of PharmaCielo Colombia Holdings S.A.S.
In its award of this recognition to Flores El Capiro the jury praised the company for its leadership on the world stage with its sea-freight program. PharmaCielo looks forward to both directors continuing to contribute that innovation and leadership to our objective of bringing medicinal-grade cannabis oil extracts and related products to the world.
About PharmaCielo Ltd.
PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.
This press release may contain forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company’s products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.